<DOC>
	<DOCNO>NCT01222767</DOCNO>
	<brief_summary>This phase II Multicenter , Open-label , Clinical Pharmacokinetic Study Zalypsis® ( PM00104 ) Patients Unresectable Locally Advanced and/or Metastatic Ewing Family Tumors ( EFT ) Progressing After Least One Prior Line Chemotherapy determine antitumor activity Zalypsis .</brief_summary>
	<brief_title>Study Zalypsis® ( PM00104 ) Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family Tumors ( EFT ) Progressing After Least One Prior Line Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<criteria>1 . Voluntary write informed consent , obtain patient his/her representative begin specific study procedure . 2 . Age ≥ 16 year . 3 . Histologically cytologically confirm EFT ( Ewing Family Tumors ) , recurrent disease . 4 . Documented failure least one prior chemotherapy regimen disease . 5 . Radiographic documentation disease progression study entry . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) score ≤ 2 . 7 . Life expectancy ≥ 3 month . 8 . Complete recovery effect drugrelated adverse event ( AEs ) derive previous treatment , exclude alopecia grade 1 peripheral neuropathy , accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) v. 4.0 . 9 . At least one measurable lesion ( `` target lesion '' accord RECIST v.1.1 ) , locate nonirradiated area adequately measure less four week study entry . Tumors within previously irradiate field designate `` nontarget '' lesion unless progression clearly document biopsy proven . 10 . Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/l ; platelet count ≥ 100 x 109/l , hemoglobin ≥ 9 g/dl . 11 . Adequate renal function : calculated creatinine clearance ( use Cockcroft Gault 's formula ) ≥ 30 ml/min . 12 . Adequate hepatic function : Total bilirubin ≤ 1.5 x upper limit normality ( ULN ) , unless due Gilbert 's syndrome . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤ 3 x ULN ( ≤ 5 x ULN case hepatic metastasis ) , alkaline phosphatase ( AP ) ≤ 2.5 x ULN ( ≤ 5 x ULN case extensive bone involvement ) . Albumin ≥ 25 g/l . 13 . Left ventricular ejection fraction ( LVEF ) within normal limit ( LVEF least 50 % ) . 14 . Women childbearing potential must negative serum pregnancy test study entry . Both woman men must agree use medically acceptable method contraception throughout treatment period three month discontinuation treatment . Acceptable method contraception include complete abstinence , intrauterine device ( IUD ) , oral contraceptive , subdermal implant double barrier ( condom contraceptive sponge contraceptive suppository ) . 1 . Prior therapy Zalypsis® . 2 . Pregnant lactate woman woman childbearing potential use appropriate contraceptive method . 3 . Less three week prior radiation therapy , biological therapy chemotherapy . 4 . Less six week prior nitrosourea , mitomycin C , highdose chemotherapy radiotherapy involve whole pelvis 50 % spine , provide acute effect radiation treatment resolve . Hormonal therapy palliative radiation therapy ( i.e. , control pain bone metastasis ) must discontinue study entry . 5 . Patients prior invasive malignancy ( except nonmelanoma skin cancer situ cervix carcinoma ) evidence disease within last five year whose prior malignancy treatment contraindicate current protocol therapy . 6 . Evidence progressive symptomatic central nervous system ( CNS ) metastases leptomeningeal metastasis . 7 . Other disease serious condition : Increased cardiac risk , define : Unstable angina myocardial infarction within 12 month inclusion study . New York Heart Association ( NYHA ) grade II great congestive heart failure . Symptomatic arrhythmia arrhythmia require ongoing treatment . Abnormal electrocardiogram ( ECG ) , i.e. , patient follow exclude : QT prolongation QTc &gt; 480 msec ; sign cardiac enlargement hypertrophy ; bundle branch block ; partial block ; sign ischemia necrosis , Wolff Parkinson White pattern . History presence valvular heart disease . Uncontrolled arterial hypertension despite optimal medical therapy . Previous mediastinal radiotherapy . Previous treatment doxorubicin cumulative dos exceed 400 mg/m2 . History significant neurological psychiatric disorder . Active infection require systemic treatment . Significant nonneoplastic liver disease ( e.g. , cirrhosis ) . Known hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection . Immunocompromised patient , include know infected human immunodeficiency virus ( HIV ) . Uncontrolled ( i.e. , require relevant change medication within last month hospital admission within last three month ) endocrine disease ( e.g. , diabetes mellitus , hypo hyperthyroidism , adrenal disorder ) . 8 . Any major illness , Investigator 's judgment , substantially increase risk associate patient 's participation study . The Investigator feel free consult Study Coordinator Sponsor ( ) case uncertainty regard . 9 . Limitation patient 's ability comply treatment followup participate center . Patients enrol trial must treat follow participate center . 10 . Treatment investigational product within 30 day prior inclusion study . 11 . Known hypersensitivity component Zalypsis® .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>EFT</keyword>
	<keyword>PNET</keyword>
	<keyword>EOE</keyword>
</DOC>